KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Cash from Operations: 2009-2025

Historic Cash from Operations for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Sep 2025 value amounting to $368.7 million.

  • Biomarin Pharmaceutical's Cash from Operations rose 66.46% to $368.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $914.0 million, marking a year-over-year increase of 120.40%. This contributed to the annual value of $572.8 million for FY2024, which is 259.69% up from last year.
  • According to the latest figures from Q3 2025, Biomarin Pharmaceutical's Cash from Operations is $368.7 million, which was up 99.00% from $185.3 million recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Cash from Operations registered a high of $368.7 million during Q3 2025, and its lowest value of -$73.9 million during Q1 2023.
  • Over the past 3 years, Biomarin Pharmaceutical's median Cash from Operations value was $135.6 million (recorded in 2023), while the average stood at $132.8 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first surged by 847.08% in 2021, then tumbled by 140.02% in 2022.
  • Over the past 5 years, Biomarin Pharmaceutical's Cash from Operations (Quarterly) stood at $11.2 million in 2021, then crashed by 39.30% to $6.8 million in 2022, then spiked by 305.00% to $27.5 million in 2023, then surged by 575.42% to $185.6 million in 2024, then soared by 66.46% to $368.7 million in 2025.
  • Its last three reported values are $368.7 million in Q3 2025, $185.3 million for Q2 2025, and $174.4 million during Q1 2025.